

(2) Items and Amounts of Extraordinary Profits and Losses

— 2023 年 9 月 30 日 2023 年 9 月 30 日

Currency: RMB Unit: Yuan

Items	Amounts from the third quarter of 2023	Amounts from the beginning of the year to the end of the Reporting Period	Description
<p>1. 非经常性损益</p>			
<p>2. 非流动资产处置损益</p>			
<p>3. 计入当期损益的政府补助</p>			<p>计入当期损益的政府补助</p>
<p>4. 其他</p>			
<p>5. 其他</p>			
<p>6. 其他</p>			
<p>7. 其他</p>			

e r r a e m ce e e r r r r r r e a

—

e r r a e m ce e e r r r r r r e a

e r r a e m ce e e r r r r r r e a

—

e r r a e m ce e e r r r r r r e a

(3) Changes in Key Accounting Data and Financial Indicators and Reasons

— 2017 2016

1. Balance sheet items

Currency: RMB Unit: Yuan

Items	As at the end of the Reporting Period	As at the end of last year	Year-on-year increase/decrease	Reasons for changes
流动资产				流动资产增加
货币资金				货币资金增加
应收账款				应收账款增加
其他应收款				其他应收款增加
存货				存货增加
流动资产合计				流动资产增加
非流动资产				非流动资产增加
长期股权投资				长期股权投资增加
固定资产				固定资产增加
无形资产				无形资产增加
非流动资产合计				非流动资产增加
资产总计				资产总计增加
流动负债				流动负债增加
应付账款				应付账款增加
其他应付款				其他应付款增加
流动负债合计				流动负债增加
非流动负债				非流动负债增加
长期借款				长期借款增加
非流动负债合计				非流动负债增加
负债合计				负债合计增加
所有者权益				所有者权益增加
实收资本				实收资本增加
未分配利润				未分配利润增加
所有者权益合计				所有者权益增加
负债和所有者权益总计				负债和所有者权益总计增加

2. Income statement items

Items	From the beginning of the year to the end of the Reporting Period	Same period of last year	Year-on-year increase/decrease	Reasons for changes
Revenue				Revenue increased by 10% compared to the same period of last year, mainly due to the increase in sales volume.
Cost of sales				Cost of sales increased by 8% compared to the same period of last year, mainly due to the increase in sales volume.
Gross profit				Gross profit increased by 2% compared to the same period of last year, mainly due to the increase in sales volume.
Selling and distribution expenses				Selling and distribution expenses increased by 5% compared to the same period of last year, mainly due to the increase in sales volume.
Administrative expenses				Administrative expenses increased by 3% compared to the same period of last year, mainly due to the increase in sales volume.
Finance expenses				Finance expenses increased by 1% compared to the same period of last year, mainly due to the increase in sales volume.
Finance income				Finance income increased by 0.5% compared to the same period of last year, mainly due to the increase in sales volume.
Income before income tax				Income before income tax increased by 1.5% compared to the same period of last year, mainly due to the increase in sales volume.

3. Cash flow items

Items	From the beginning of the year to the end of the Reporting Period	Same period of last year	Year-on-year increase/decrease	Reasons for changes
<p>Operating activities</p>				<p>Operating activities</p>
<p>Investing activities</p>				<p>Investing activities</p>
<p>Financing activities</p>				<p>Financing activities</p>

BUSINESS REVIEW

The first part of the review covers the period from the beginning of the year to the end of the first quarter. It discusses the overall performance of the company, including sales, production, and financial results. The second part of the review covers the period from the beginning of the second quarter to the end of the year. It discusses the company's performance during this period, including any changes in sales, production, and financial results. The third part of the review covers the company's performance during the year, including any changes in sales, production, and financial results. The fourth part of the review covers the company's performance during the year, including any changes in sales, production, and financial results.

The first part of the review covers the period from the beginning of the year to the end of the first quarter. It discusses the overall performance of the company, including sales, production, and financial results. The second part of the review covers the period from the beginning of the second quarter to the end of the year. It discusses the company's performance during this period, including any changes in sales, production, and financial results. The third part of the review covers the company's performance during the year, including any changes in sales, production, and financial results. The fourth part of the review covers the company's performance during the year, including any changes in sales, production, and financial results.

The first part of the review covers the period from the beginning of the year to the end of the first quarter. It discusses the overall performance of the company, including sales, production, and financial results. The second part of the review covers the period from the beginning of the second quarter to the end of the year. It discusses the company's performance during this period, including any changes in sales, production, and financial results. The third part of the review covers the company's performance during the year, including any changes in sales, production, and financial results. The fourth part of the review covers the company's performance during the year, including any changes in sales, production, and financial results.

Heparin Industrial Chain Business

The heparin industrial chain business is a complex and highly regulated industry. It involves the production, distribution, and use of heparin, a naturally occurring glycosaminoglycan that is used as an anticoagulant in various medical applications. The industry is characterized by a high degree of specialization and a long history of research and development.

The heparin industrial chain begins with the extraction of heparin from porcine intestinal mucosa. This process involves a series of steps, including the isolation of the mucosa, the extraction of heparin, and the purification of the heparin. The resulting heparin is then used in a variety of applications, including the production of heparin sulfate, heparin sodium, and heparin calcium.

The heparin industrial chain is a highly competitive market, with a number of major players. These players include pharmaceutical companies, biotechnology companies, and chemical companies. The industry is also characterized by a high degree of regulation, with strict requirements for the production and distribution of heparin.

The heparin industrial chain is a complex and highly regulated industry. It involves the production, distribution, and use of heparin, a naturally occurring glycosaminoglycan that is used as an anticoagulant in various medical applications. The industry is characterized by a high degree of specialization and a long history of research and development.

CDMO BUSINESS

The CDMO business is a highly competitive and capital-intensive industry. It involves the development, manufacturing, and distribution of pharmaceutical products. The market is characterized by high barriers to entry, including significant R&D costs and regulatory requirements. Key players in the industry include large pharmaceutical companies and specialized CDMOs. The business is subject to fluctuations in demand and pricing, particularly in the generic drug market. The overall outlook for the CDMO business is positive, driven by the growing need for pharmaceutical products and the increasing reliance on CDMOs for manufacturing and distribution.

OUTLOOK

The outlook for the CDMO business is positive, driven by the growing need for pharmaceutical products and the increasing reliance on CDMOs for manufacturing and distribution. The market is expected to continue to grow, with significant opportunities for expansion in emerging markets. Key factors driving the growth of the CDMO business include the increasing complexity of pharmaceutical products, the need for specialized manufacturing capabilities, and the growing emphasis on cost efficiency. The industry is also benefiting from the increasing use of contract manufacturing and distribution services. However, the CDMO business is also facing challenges, including intense competition, regulatory changes, and fluctuations in demand. The overall outlook for the CDMO business is positive, with significant opportunities for growth and expansion.

(2) Statement of the total number of preferred shareholders of the Company and shareholdings of the top 10 preferred shareholders

2023年9月30日 — 2023年9月30日

III. OTHER IMPORTANT EVENTS

2023年9月30日 — 2023年9月30日

IV. QUARTERLY FINANCIAL STATEMENTS

(1) Financial Statements

1. Consolidated Balance Sheet

截至2023年9月30日止的合并资产负债表

September 30, 2023

Currency: RMB Unit: Yuan

Items	September 30, 2023	人民币
Current assets:		
货币资金	1,791,292,771.63	
应收账款		
预付款项		
其他应收款	474,182,329.41	
存货	-	
流动资产合计	6,208,009.76	
长期股权投资	1,241,350,011.62	
固定资产	-	
无形资产	153,083,541.29	
递延所得税资产		
其他非流动资产		
非流动资产合计	110,912,922.00	
资产总计	-	
负债和所有者权益	-	

Items	September 30, 2023	2022
Accounts receivable		
Inventory	7,805,326,066.17	
Prepaid expenses	10,623,409.64	
Other current assets		
Property, plant and equipment		
Intangible assets	266,104,811.21	
Financial assets	11,859,083,872.73	
Non-current assets:		
Investments		
Other non-current assets	-	
Deferred tax assets	-	
Other non-current assets	1,070,390.11	
Other non-current assets	666,685,804.22	
Other non-current assets	515,024,324.71	
Other non-current assets	1,054,981,140.44	
Other non-current assets	-	
Other non-current assets	2,150,962,742.89	
Other non-current assets	352,770,797.25	
Other non-current assets	-	
Other non-current assets	-	
Other non-current assets	118,796,156.63	
Other non-current assets	490,667,506.89	
Other non-current assets	53,090,539.67	
Other non-current assets	2,423,635,646.83	
Other non-current assets	190,843,267.93	
Other non-current assets	154,763,710.53	
Other non-current assets	88,275,110.64	
Other non-current assets	8,261,477,138.74	
Other non-current assets	20,120,561,011.47	

Items	September 30, 2023	2022
Current liabilities:		
Accounts payable	1,820,787,926.49	
Accounts receivable		
Accrued expenses		
Deferred income taxes	-	
Other current liabilities	-	
Short-term debt	34,670,511.89	
Long-term debt	213,336,725.01	
Other non-current liabilities	-	
Other liabilities	403,990,704.82	
Other non-current liabilities		
Other non-current liabilities		
Other non-current liabilities		
Other non-current liabilities	117,087,892.28	
Other non-current liabilities	127,715,875.39	
Other non-current liabilities	398,847,341.16	
Other non-current liabilities	-	
Other non-current liabilities	122,690,265.17	
Other non-current liabilities		
Other non-current liabilities		
Other non-current liabilities	1,880,754,618.38	
Other non-current liabilities	-	
Other non-current liabilities	4,997,191,595.42	
Non-current liabilities:		
Long-term debt		
Accounts payable	2,116,802,507.02	
Accounts receivable	-	
Accrued expenses	-	
Deferred income taxes	-	
Other current liabilities	-	

Items	September 30, 2023	2022
Current assets	92,624,776.83	
Prepaid expenses	395,725.24	
Accounts receivable	40,293,108.90	
Inventory	9,876,817.34	
Other assets	29,751,781.75	
Investments	334,582,068.96	
Property, plant, and equipment	-	
Intangible assets	2,624,326,786.04	
Other non-current assets	7,621,518,381.46	
Owners' equity:		
Common stock	1,467,296,204.00	
Retained earnings	-	
Accumulated other comprehensive income	-	
Other equity	-	
Preferred stock	5,854,583,773.47	
Other equity	-	
Other equity	226,528,230.35	
Other equity		
Other equity	545,376,458.31	
Other equity		
Other equity	4,312,374,190.99	
Other equity	12,406,158,857.12	
Other equity	92,883,772.89	
Other equity	12,499,042,630.01	
Other equity	20,120,561,011.47	

Other equity

Other equity

Other equity

2. Consolidated Income Statement from the beginning of the year to the end of the Reporting Period

Currency: RMB Unit: Yuan

Items	Amount for current period	
营业收入	4,063,233,063.48	
营业成本	4,063,233,063.48	
营业税金及附加		
销售费用		
管理费用		
财务费用		
资产减值损失	3,669,009,984.63	
公允价值变动收益	2,720,675,046.08	
投资收益		
营业外收入		
营业外支出		
利润总额		
所得税费用		
净利润	12,802,583.40	
其他综合收益	402,920,606.39	
综合收益总额	306,237,517.82	
归属于母公司所有者的综合收益总额	152,223,825.20	
归属于少数股东的综合收益总额	74,150,405.74	
净利润	172,185,286.54	
其他综合收益	34,032,251.07	
综合收益总额	20,383,283.61	
归属于母公司所有者的综合收益总额	-274,834,971.73	
归属于少数股东的综合收益总额	-283,240,300.17	
综合收益总额	-	

Items	Amount for current period	Amount for previous period
Αμοιβή για υπηρεσίες -		
Αμοιβή για υπηρεσίες -	-	
Αμοιβή για υπηρεσίες -	37,143,775.77	
Αμοιβή για υπηρεσίες -	-3,097,694.49	
Αμοιβή για υπηρεσίες -	5,551,276.16	
Αμοιβή για υπηρεσίες -	-549,392.43	
Αμοιβή για υπηρεσίες -	178,819,355.74	
Αμοιβή για υπηρεσίες -	6,458,415.02	
Αμοιβή για υπηρεσίες -	4,102,908.74	
Αμοιβή για υπηρεσίες -	181,174,862.02	
Αμοιβή για υπηρεσίες -	39,289,379.06	
Αμοιβή για υπηρεσίες -	141,885,482.96	
Αμοιβή για υπηρεσίες -		
Αμοιβή για υπηρεσίες -	141,885,482.96	
Αμοιβή για υπηρεσίες -	-	
Αμοιβή για υπηρεσίες -		
Αμοιβή για υπηρεσίες -	143,170,121.26	
Αμοιβή για υπηρεσίες -	-1,284,638.30	
Αμοιβή για υπηρεσίες -	101,092,675.13	
Αμοιβή για υπηρεσίες -	101,005,511.82	
Αμοιβή για υπηρεσίες -	-3,008,947.26	
Αμοιβή για υπηρεσίες -	2,251,161.67	
Αμοιβή για υπηρεσίες -	-	

3. Consolidated Cash Flow Statement from the beginning of the year to the end of the Reporting Period

Currency: RMB Unit: Yuan

Items	Amount for current period	Amount for prior period
经营活动产生的现金流量		
销售商品、提供劳务收到的现金	4,603,550,675.54	
收到的税费返还		
收到其他与经营活动有关的现金		
购买商品、接受劳务支付的现金		
支付给职工以及为职工支付的现金		
支付的各项税费		
支付其他与经营活动有关的现金		
经营活动现金流出小计		
经营活动产生的现金流量净额	206,974,609.19	
投资活动产生的现金流量		
收回投资收到的现金	47,790,265.82	
取得投资收益收到的现金	4,858,315,550.55	
处置固定资产、无形资产和其他长期资产收回的现金净额	3,633,091,884.41	
处置子公司及其他营业单位收到的现金净额		
收到其他与投资活动有关的现金		
购建固定资产、无形资产和其他长期资产支付的现金		
投资支付的现金		
取得子公司及其他营业单位支付的现金净额		
支付其他与投资活动有关的现金		
投资活动现金流出小计		
投资活动产生的现金流量净额	673,352,520.02	
筹资活动产生的现金流量		
吸收投资收到的现金	210,215,294.50	
取得借款收到的现金	575,644,822.54	
发行债券收到的现金	5,092,304,521.47	
收到其他与筹资活动有关的现金		
偿还债务支付的现金		
分配股利、利润或偿付利息支付的现金		
支付其他与筹资活动有关的现金		
筹资活动现金流出小计		
筹资活动产生的现金流量净额	-233,988,970.92	

Items	Amount for current period	Amount for prior period
	1,494,880,389.45	
	32,344,822.97	
	2,323,756.31	
	-	
	771,783,056.20	
	2,301,332,024.93	
	274,837,032.45	
	683,038,740.26	
	-	
	31,117,972.12	
	988,993,744.83	
	1,312,338,280.10	
	-	
	-	
	3,557,251,571.62	
	150,342,810.61	
	3,707,594,382.23	
	4,097,326,290.58	
	250,602,018.90	
	-	
	31,764,577.78	
	4,379,692,887.26	
	-672,098,505.03	
	31,821,093.12	
	438,071,897.27	
	1,319,707,185.95	
	1,757,779,083.22	

Items	September 30, 2023	January 1, 2023	Adjustments	December 31, 2022
	7,805,326,066.17			
	10,623,409.64			
	266,104,811.21			
	11,859,083,872.73			
Non-current assets:				
	1,070,390.11			
	666,685,804.22			
	515,024,324.71			
	1,054,981,140.44			
	2,150,962,742.89			
	352,770,797.25			
	118,796,156.63			
	490,667,506.89			
	53,090,539.67			
	2,423,635,646.83			
	190,843,267.93			
	154,673,710.53			
	88,275,110.64			
	8,261,477,138.74			
	20,120,561,011.47			

Items	September 30, 2023	January 1, 2023	Adjustments	December 31, 2022
Current liabilities:				
Accounts payable	1,820,787,926.49			
Short-term debt				
Accrued interest				
Accrued expenses				
Income taxes payable				
Deferred income taxes	34,670,511.89			
Other current liabilities	213,336,725.01			
Long-term debt	403,990,704.82			
Long-term debt - non-current				
Other long-term liabilities				
Other long-term liabilities - non-current				
Other long-term liabilities - non-current				
Other long-term liabilities - non-current	117,087,892.28			
Other long-term liabilities - non-current	127,715,875.39			
Other long-term liabilities - non-current	398,847,341.16			
Other long-term liabilities - non-current				
Other long-term liabilities - non-current	122,690,265.17			
Other long-term liabilities - non-current				
Other long-term liabilities - non-current				
Other long-term liabilities - non-current				
Other long-term liabilities - non-current	1,880,754,618.38			

Items	September 30, 2023	January 1, 2023	Adjustments	December 31, 2022
Current liabilities:				
Accounts payable	4,997,191,595.42			
Non-current liabilities:				
Long-term debt				
Deferred tax liabilities	2,116,802,507.02			
Other non-current liabilities				
Current assets:				
Accounts receivable	92,624,776.83			
Prepaid expenses	395,725.24			
Other current assets	40,293,108.90			
Property, plant, and equipment	9,876,817.34			
Intangible assets	29,751,781.75			
Other non-current assets	334,582,068.96			
Equity:				
Common stock	2,624,326,786.04			
Retained earnings	7,621,518,381.46			
Owners' equity:				
Common stock	1,467,296,204.00			
Retained earnings				
Other equity				
Other equity				
Other equity	5,854,583,773.47			
Other equity				
Other equity	226,528,230.35			

Items	September 30, 2023	January 1, 2023	Adjustments	December 31, 2022
	545,376,458.31			
	4,312,374,190.99			
	12,406,158,857.12			
	92,883,772.89			
	12,499,042,630.01			
	20,120,561,011.47			

(3) Audit Report

e e r e r r i e r a , r i e e e i e
 e r r i e r a , r e e e e e e e e
 e r r i e r a , r e e e e e e e e
 e r r i e r a , r e e e e e e e e
 e r r i e r a , r e e e e e e e e